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Background and aims: We assess the respective relationship of high depressive symptoms and antide-
pressant use (ATD) with baroreﬂex sensitivity (BRS) in subjects from the community who enrolled the
Paris Prospective Study III.
Methods: Recruitment took place in a large health preventive centre in Paris (France), between May 2008
and June 2012. BRS was investigated by spectral analysis of the spontaneous carotid distension rate and
RR intervals using non-invasive high-resolution ultrasound carotid-echotracking. A total score 7 on a
13-item standardized questionnaire deﬁned the presence of high depressive symptoms. Information on
ATD use was obtained on a face-to-face interview with a medical doctor who checked the most recent
medical prescriptions and/or medical package.
Results: There were 9213 participants aged 50e75 years (38.6% of women), including 5.6% with high-
depressive symptoms and 5.2% on ATD. High depressive symptoms were not associated with low BRS
(below the median) even in unadjusted logistic regression analysis (OR ¼ 1.09; 95%CI: 0.91e1.30).
Instead, ATD use was related to low BRS in multivariate logistic regression analysis (OR ¼ 1.27; 95% CI:
1.04e1.54). This association remains after adjusting for and matching on propensity score of receiving
ATD. A speciﬁc association with serotonin and norepinephrine reuptake inhibitors was observed
(OR ¼ 1.94; 95% CI: 1.16e3.22).
Conclusions: ATD use and serotonin and norepinephrine reuptake inhibitors in particular, but not high
depressive symptoms, is associated with low BRS. If conﬁrmed, these results may bring novel insights
into the mechanisms linking depressive symptoms and/or ATD use with cardiovascular disease onset.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rtment of Epidemiology, 56
J.-P. Empana).
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Depression and high depressive symptoms are very common in
the population and are expected to rise given the aging of the
population [1]. Likewise, antidepressants (ATD) are now one of the
most prescribed medications worldwide [2]. A large body of evi-
dence indicates that depression and high depressive symptoms are
related to the onset of cardiovascular disease (CVD) and particularly
sudden cardiac death (SCD) [3e5]. Regarding ATD use, the pro-
arrhythmic effect of tricyclics and their association with SCD has
been already reported; some selective serotonin reuptake in-
hibitors (SSRI) could be linked with an increased risk of SCD as well
[6,7]. So far however, the disease processes by which depressive
symptoms and/or ATD use might be related to CVD onset including
SCD remain to be further investigated. Poor lifestyle risk factors,
lack of adherence to medical treatment, increased platelet aggre-
gation or chronic low-grade inﬂammation, have been proposed as
possible explanations, but with mixed evidence [8e10]. We hy-
pothesize that autonomic dysfunction and impairment in the
baroreceptor reﬂex sensitivity (BRS) in particular could represent
one relevant disease process to investigate. The BRS is a funda-
mental key process for the homeostasis of blood pressure and heart
rate variability (HRV), and is one of the strongest risk factor for SCD
in post myocardial infarction patients [11]. The extent to which
depression and/or ATD use is associated with impaired BRS per se
has been addressed by only a few studies that although contrib-
uting, suffer from the following limitations. They were of very
limited sample size (n < 100), mostly conducted in patients with
coronary artery disease (CAD) or elderly participants and only a few
addressed the inﬂuence of ATD use [12e15]. Several population
based studies have reported higher resting heart rate and
decreased HRV- that are strong predictors of CVD mortality and
SCD- [1618] in ATD users and possibly subjects with depressive
symptoms [19e24]. However, heart rate markers and HRV param-
eters only represent the efferent loop of the BRS.
We therefore aimed to study the respective association of high
depressive symptoms and ATD use with BRS in more than nine
thousands unselected participants who enrolled the Paris Pro-
spective Study III [25].
2. Materials and methods
2.1. The Paris Prospective Study 3
The design and main objectives of the PPSIII have been previ-
ously published [25]. It is an ongoing prospective observational
cohort on the novel determinants of the onset of main phenotypes
of CVD in initially mostly healthy subjects. Our study is registered in
theWorld Health Organization International Trial Registry Platform
(NCT00741728 since 25/08/2008). The study-protocol was
approved by the Ethics Committee of the Cochin Hospital (Paris).
Between May, 2008 and June, 2012, 10,157 men and women aged
50e75 years were recruited in a large preventive medical centre,
the Centre d’Investigations Preventives et Cliniques (IPC), in Paris
(France) after signing an informed consent form. The IPC is a pre-
ventive medical centre that is subsidized by the French National
Insurance System for Salaried Workers (Securite Sociale-CNAMTS),
which offers to all working and retired employees and their fam-
ilies living in the Paris area, a free medical examination every ﬁve
years. The standard health check-up includes a complete clinical
examination, coupled with standard biological tests after an over-
night fasting. A self-administered questionnaire provides infor-
mation related to professional activity, lifestyle (tobacco and
alcohol consumption, physical activity, diet, etc.), personal and
family medical history, current health status and medicationconsumption [26].
2.2. Depressive symptoms
Since the late 80s, all preventive health centres subsidized by
the French National Insurance System for Salaried Workers in
France use the 13-item Questionnaire of Depression 2nd version,
Abridged (QD2A) [27] to screen individuals from the community
who are at high risk of depression. This questionnaire was initially
based on 151 items selected from 4 self-rating scales or inventories
of depression used in clinical settings: the Beck Depression In-
ventory [28], the Zung Self-Rating Depression Scale [29], the D
Scale of Depression of the Minnesota Multiphasic Personality In-
ventory (MMPI) [30], and the Hopkins Symptoms Check list [31].
After principal component analysis, 52 items were retained; a
subsequent factorial analysis demonstrates that an abridged
version with 13 items summarized satisfactorily the severity of
depressive symptoms. This 13-item questionnaire has been vali-
dated against clinically diagnosed depression [32]. In particular
these 13-items cover 2 dimensions, motivation and depressive
mood. Participants had to give a yes/no answer to each of the 13-
item regarding their current emotional state (e.g. “I am disap-
pointed and disgusted with myself”, “I am sad these days”, “I feel
hopeless about the future”). The number of yes answers is summed
to provide a total score with high internal consistency (a ¼ 0.91). A
total score 7 indicates a high probability for major depression
(sensitivity: 81%, speciﬁcity: 96%) and will be referred to as “high
depressive symptoms” in the following sections [27]. The 13-item
questionnaire is reported in the Supplementary ﬁle.
2.3. Medications
On a standardized questionnaire, participants reported up to 15
medications they were currently taking, together with a series of
chronic conditions including depression for which they were
currently prescribed medications. To reduce under reporting, par-
ticipants were asked to come at the IPC with either their most
recent medical prescriptions and/or with their medical package.
Medications were checked by a medical doctor from the IPC during
a face to face interview with the study participant. Medications
were coded using the World Health Organization (WHO)
Anatomical Therapeutic Chemical (ATC) classiﬁcation. For the
present analysis, ATD were classiﬁed as SSRI, serotonin and
norepinephrine reuptake inhibitors (SNRI), tricyclic antidepres-
sants (TCAs), and other antidepressant drugs.
2.4. Echotracking-derived neural baroreﬂex sensitivity
Because baroreceptors are more sensitive to arterial stretch (i.e.
deformation) than pressure per se, BRS can be investigated by the
spectral analysis of the spontaneous carotid distension ﬂuctuations
(input signal) and RR intervals (output signal) using non-invasive
high-resolution ultrasound carotid-echotracking [33e35]. With
this technique, the neural component of the BRS is estimated, while
controlling for its vascular (i.e. mechanical) component, i.e. the
stiffness of the artery [34e36]. This method has been shown to be
highly consistent with other noninvasive BRS assessment methods
[37]. A detailed description of the measures is given in the sup-
plementary materials. Brieﬂy, measurements were performed at
the right common carotid artery (CCA) 1 cm proximal to the carotid
bulb bifurcation using the ArtLab® (Esaote, Italy) high-resolution
echotracking technology after 100 of rest in a supine position. A 5-
min continuous recording of carotid diameter and distension was
performed: cross spectral analysis of distension rate and heart rate
was performed, extracting low frequency (LF) and high frequency
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transfer function magnitude between input (carotid distension
rate) and output (R-R interval) within the frequency band of
0.04e0.15 Hz deﬁned the LF gain and corresponds to the neural BRS
(nBRS) [38,39]. In the absence of any published thresholds, we
deﬁned low nBRS as a value below the median, which was calcu-
lated in the entire participant population.
2.5. Study population
Among the 10157 subjects examined at baseline, 832 had
incomplete nBRS measures, 70 had missing values on ATD intake
and 50 on depressive symptoms score. Excluded subjects were
older, more frequently women, had a signiﬁcantly higher burden of
cardiovascular risk factors (all p values < 0.05) and tended to be
prescribed ATD more frequently (p ¼ 0.06) than the ﬁnally inves-
tigated 9213 subjects (Supplementary Table 1).
2.6. Statistical analysis
Characteristics between subjects with and without high
depressive symptoms, with and without ATD use or with and
without low nBRS (log transformed times 100) were compared
using Pearson chi-square and t-test for categorical and continuous
variables respectively. In the following analyses, nBRS was used as
the outcome and high depressive symptoms or ATD use as themain
exposure variables. Separate logistic regression analysis was
employed to quantify the association between high depressive
symptoms or ATD use with low nBRS. Analyses were adjusted for
established confounding factors including age, sex, past history of
CVD, education, single status, smoking status, hypertension, dia-
betes, body mass index, resting heart rate, and physical activity.
Subsequent analyses focused on ATD use for which signiﬁcant as-
sociations were observed. Associations between ATD use and low
nBRS, were stratiﬁed by sex, age group (according to median age),
hypertension, high depressive symptoms, personal history of CVD
and resting heart rate levels (according to median value); in-
teractions across strata were evaluated using a p value of <0.10 as
potentially relevant. Given the observational nature of the study,
and to minimize for indication bias for ATD prescription, the as-
sociation between ATD use and low nBRS was further conducted
using propensity score analysis [40]. The propensity of receiving
ATD of any class was estimated by logistic regression analysis using
age, sex, education, single status, prevalent CVD, smoking status,
hypertension, diabetes, body mass index, resting heart rate, phys-
ical activity and high depressive symptoms as covariates on an a
priori basis. Then, the association between ATD use and low nBRS
was repeated after adjustment for the propensity score and after
propensity score matching. [40] For the latter, 1 subject under ATD
was matched with up to 4 controls using a difference in the prob-
ability of receiving ATD of less than 0.001, resulting in a study
sample size of 2098 subjects after matching. Sensitivity analyses
were conducted to assess the robustness of our ﬁndings on ATD use
and nBRS. First, nBRS was considered as a continuous outcome (log
transformed) and its association with ATD use was carried out in
multivariable linear regression analyses after adjustment for the
same above mentioned confounding factors. Second, nBRS was
considered in quartiles and its associationwith ATD usewas carried
out in multivariable multinomial ordinal logistic regression anal-
ysis. In exploratory analysis, the association between low nBRS and
ATD class - available in 71.6% of the ATD users - including SSRIs,
SNRIs, TCAs and other antidepressants was quantiﬁed in separate
multivariable logistic regression analyses using those not under
ATD as the reference category. To minimize the impact of missing
information on ATD class, a dummy variable indicator for missinginformation for ATD class was included in each model. All tests
were two-sided andwere performed using SAS software release 9.4
(Statistical Analysis System, Cary, NC, USA).
3. Results
3.1. Baseline characteristics
The mean age (standard deviation SD) of the population was
59.5 (6.30), 38.6% were women and 2% reported a past history of
CVD. 5.6% of the participants had high-depressive symptoms and
5.2% were on ATD. The characteristics of the population by
depressive symptoms status and by ATD use are reported in
Table 1. As expected, womenwere more often depressed and more
often prescribed ATD than men; subjects with high depressive
symptoms were prescribed ATD ﬁve times more frequently than
subjects without depressive symptoms, and subjects under ATD
were ﬁve times more often depressed than non-users. Further-
more, subjects with high depressive symptoms and subjects on
ATD had signiﬁcantly worse characteristics than their respective
comparison group. ATD users had signiﬁcantly lower nBRS and
higher CCA-IMT compared to non-users, whereas these 2 pa-
rameters did not differ between subjects with and without high
depressive symptoms.
Among ATD users, 57.7% were on SSRI, 22.7% on SNRI, 15.6% on
TCAs, and the remaining on other ATDs. The distribution of the
baseline characteristics by ATD class is reported in Supplementary
Table 2 and shows in particular that SNRI users had higher systolic
blood pressure, higher CCA-IMT, higher resting heart rate and were
less physically active than ATD users of other class.
Table 2 shows the baseline characteristics between subjects
with low (below the median) and high nBRS (above the median).
Subjects with low nBRS were older, more frequently women, less
educated, more often with a personal history of CVD, more
frequently diabetics or hypertensive, had higher BMI, higher resting
heart rate, and were more often on ATD, especially SNRI, compared
to subjects with higher nBRS. Interestingly, the prevalence of high
depressive symptoms did not differ between subjects with high
and low nBRS.
3.2. Odds ratios of high depressive symptoms for low nBRS
As illustrated in Fig. 1 there was no signiﬁcant association be-
tween high depressive symptoms and low nBRS. This was observed
even in unadjusted analysis (OR ¼ 1.09; 95%CI: 0.91e1.30) and
when the populationwas restricted to those not on ATD (OR¼ 1.01;
95% CI: 0.82e1.25).
3.3. Odds ratio of antidepressant use for low nBRS
3.3.1. Classical analysis
As shown in Fig. 1, there was a statistically signiﬁcant associ-
ation between ATD use and low nBRS (OR ¼ 1.34; 95% CI:
1.11e1.62) in unadjusted analysis, which was virtually unchanged
after adjustment for confounding factors (OR ¼ 1.27; 95% CI:
1.05e1.55). Further adjustment for high depressive symptoms
slightly attenuated the association with ATD (OR ¼ 1.27; 95% CI:
1.04e1.54). As shown in Table 3, the magnitude of the association
between ATD use and low nBRS was comparable to that with
hypertension or diabetes and was equivalent to the effect of 8
years of ageing. As shown in Fig. 2, the multivariate-adjusted as-
sociation, between ATD use and low nBRS was consistent across
strata deﬁned by age, sex, personal history of CVD, level of resting
heart rate and high depressive symptoms status. However, this
association existed in the absence of hypertension only (p for
Table 1
Baseline characteristics by depressive symptoms status and by antidepressants intake.
Depressive symptoms score pa Antidepressants intake pa
<7 (N ¼ 8699) 7 (N ¼ 514) No (N ¼ 8737) Yes (N ¼ 476)
Age (years) 59.57 (6.29) 59.08 (6.07) 0.083 59.52 (6.28) 60.06 (6.22) 0.065
Men 5464 (62.81) 190 (36.96) <0.0001 5487 (62.80) 167 (35.08) <0.0001
Marital status (single) 2144 (24.71) 243 (47.46) <0.0001 2198 (25.22) 189 (39.79) <0.0001
Education (Degree, master and þ) 3482 (40.36) 132 (26.24) <0.0001 3446 (39.79) 168 (35.74) 0.081
Personal history of cardiovascular disease 161 (1.85) 21 (4.10) 0.0004 167 (1.92) 15 (3.15) 0.06
Depressive symptoms score 7 e e e 403 (4.61) 111 (23.32) <0.0001
Antidepressants intake 365 (4.20) 111 (21.60) <0.0001
SSRIb 138 (1.61) 50 (10.31) <0.0001 0 188 (57.67) <0.0001
SNRIb 54 (0.63) 20 (4.12) <0.0001 0 74 (22.70) <0.0001
Tricyclic antidepressantsb 41 (0.48) 10 (2.06) 0.0003 0 51 (15.64) <0.0001
Otherb 23 (0.27) 5 (1.03) 0.015 0 28 (8.59) <0.0001
Physically active 6925 (79.61) 361 (70.23) <0.0001 6917 (79.17) 369 (77.52) 0.389
Current smoker 1236 (14.22) 116 (22.57) <0.0001 1251 (14.32) 101 (21.22) <0.0001
Body mass index (kg/m2) 25.12 (3.60) 25.18 (4.21) 0.729 25.13 (3.60) 25.06 (4.20) 0.723
High density lipoprotein (mg/dL) 58.35 (15.14) 59.42 (16.58) 0.157 58.26 (15.17) 61.24 (16.04) <0.0001
Total cholesterol (mg/dL) 221.27 (36.01) 221.01 (36.86) 0.874 221.02 (35.99) 225.71 (37.02) 0.006
Lipid lowering drugs 1081 (12.43) 66 (12.84) 0.784 1061 (12.15) 86 (18.07) 0.0001
Impaired fasting glycemia or diabetes 334 (3.85) 25 (4.87) 0.244 342 (3.92) 17 (3.57) 0.699
Systolic blood pressure, mmHg 130.97 (16.26) 130.37 (16.93) 0.418 131.00 (16.32) 129.86 (15.97) 0.138
Diastolic blood pressure, mmHg 75.78 (9.55) 74.84 (9.49) 0.031 75.78 (9.56) 74.68 (9.20) 0.015
Blood pressure lowering drugs 1176 (13.55) 95 (18.48) 0.002 1180 (13.54) 91 (19.12) 0.001
Heart rate (beats/min) 61.64 (8.85) 63.40 (10.34) 0.0002 61.66 (8.92) 63.10 (9.40) 0.0007
CCA-IMTc (mm) 639.61 (116.68) 641.01 (108.40) 0.777 639.13 (116.32) 649.91 (114.09) 0.049
High neural baroreﬂex sensitivityd 4360 (50.12) 247 (48.05) 0.363 4402 (50.38) 205 (43.07) 0.002
Data are reported as n (%) and mean (standard deviation) where appropriate.
SSRI: selective serotonin reuptake inhibitors; SNRI: serotonin and norepinephrine antidepressants.
a Person Chi-square test (or ﬁsher exact test) and Student test where appropriate.
b Information on ATD class could be retrieved in only 71.6% of ATD users.
c Common carotid artery intima media thickness.
d Neural baroreﬂex above the median value.
Table 2
Baseline characteristics in subjects with low (below the median) and high (greater or equal to the median) neural baroreﬂex sensitivity.
Low neural BRS (N ¼ 4606) High neural BRS (N ¼ 4607) pa
Age (years) 60.20 (6.43) 58.89 (6.06) <0.0001
Men 2763 (59.99) 2891 (62.75) 0.006
Marital status: single 1237 (26.92) 1150 (25.03) 0.039
Education level (Degree, master) 1759 (38.48) 1855 (40.69) 0.031
Personal history of cardiovascular disease 110 (2.39) 72 (1.57) 0.004
Depressive symptoms score 7 267 (5.80) 247 (5.36) 0.363
Antidepressants 271 (5.88) 205 (4.45) 0.002
SSRIb 103 (2.28) 85 (1.87) 0.174
SNRIb 49 (1.08) 25 (0.55) 0.005
Tricyclic antidepressantsb 28 (0.62) 23 (0.51) 0.472
Otherb 13 (0.29) 15 (0.33) 0.714
Physically active 3634 (78.90) 3652 (79.27) 0.659
Current smoker 703 (15.27) 649 (14.09) 0.109
Body mass index (kg/m2) 25.31 (3.78) 24.94 (3.48) <0.0001
High density lipoprotein (mg/dL) 58.73 (15.36) 58.09 (15.08) 0.045
Total cholesterol (mg/dL) 221.74 (36.39) 220.77 (35.72) 0.197
Lipid lowering drugs 664 (14.42) 483 (10.49) <0.0001
Impaired fasting glycemia or diabetes 217 (4.72) 142 (3.09) <0.0001
Systolic blood pressure, mmHg 132.66 (16.55) 129.22 (15.86) <0.0001
Diastolic blood pressure, mmHg 75.83 (9.67) 75.61 (9.42) 0.275
Blood pressure lowering drugs 735 (15.96) 536 (11.63) <0.0001
Heart rate (beats/min) 62.38 (9.09) 61.09 (8.76) <0.0001
CCA-IMTc (mm) 651.95 (116.69) 627.42 (114.46) <0.0001
Data are reported as n (%) and mean (standard deviation) where appropriate.
BRS: baroreﬂex sensitivity; SSRI: selective serotonin reuptake inhibitors; SNRI: serotonin and norepinephrine antidepressants.
a Person Chi-square test (or ﬁsher exact test) and Student test where appropriate.
b Information on ATD class could be retrieved in only 71.6% of the users.
c Common carotid artery intima media thickness.
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3.3.2. Propensity score analysis
To limit indication bias associated with ATD prescription, we
have repeated the analysis using propensity score analysis. Asreported on Fig. 3 and compared to the classical analysis reported
above, the associations between ATD use and low nBRS remained
unchanged after adjusting for (OR ¼ 1.28; 95% CI: 1.05e1.55) or
matching on (OR ¼ 1.32; 95%CI: 1.07e1.63) propensity score
respectively.
Fig. 1. Odds ratios of low neural baroreﬂex sensitivity for high depressive symptoms and antidepressant use. Separate logistic regression analysis adjusted for age, sex, ed-
ucation, single status, body mass index, resting heart rate, past history of cardiovascular disease, hypertension, diabetes, high depressive symptoms (where appropriate) and
antidepressants (where appropriate).
Table 3
Risk factors associated with low neural baroreﬂex sensitivity in multivariate logistic
regression analysis.
OR 95% CI p values
Age (/1 year) 1.03 1.02e1.04 <0.0001
Women vs. men 1.11 1.01e1.22 0.028
Single 1.05 0.95e1.16 0.366
School educationa 0.98 0.90e1.07 0.715
Never smokers 1 (ref)
Ex-smokers 1.09 0.99e1.20 0.074
Current smokers 1.22 1.08e1.39 0.002
Physically active 1.02 0.92e1.14 0.680
BMI (/1 kg/m2) 1.02 1.01e1.03 0.0009
Heart rate (/10 bpm) 1.14 1.09e1.20 <0.0001
Past history of CVD 1.26 0.93e1.71 0.143
Hypertension 1.25 1.14e1.38 <0.0001
Diabetes 1.29 1.03e1.61 0.025
High depressive symptoms 1.02 0.84e1.23 0.870
Antidepressants intake 1.27 1.04e1.54 0.018
Single logistic regression analysis adjusted for all covariates present in the Table.
Low neural baroreﬂex sensitivity is deﬁned by a baroreﬂex value lower than the
median.
bpm: beat per minutes; CVD: cardiovascular disease; BMI: body mass index.
a Degree or more.
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In separate multivariable linear regression analysis, ATD use
(regression coefﬁcient ¼ 0.079, p value ¼ 0.007) remained asso-
ciated with nBRS (log-transformed variable). Furthermore, multi-
nomial logistic regression indicates that ATD users weremore often
observed in lower quartiles of nBRS as shown by odds ratios of 0.94
(0.70e1.25), 1.12 (0.85e1.48) and 1.34 (1.03e1.76) respectively for
the third, second and ﬁrst quartile of nBRS. Likewise, the odds ratio
of ATD use for the ﬁrst versus the last three quartiles of nBRS was
1.31 (1.07e1.62; p ¼ 0.01).3.5. Exploratory analysis by ATD class
Multivariable analysis by ATD class suggests a statistically
signiﬁcant association with SNRI (OR ¼ 1.94; 95% CI: 1.16e3.22)
only. Among SNRI users (n ¼ 74 users), 64 were on Venlafaxine, 7
on Duloxetine and 3 on Milnacipran; association was observed
with venlafaxine (OR ¼ 1.67; 95% CI:0.99e2.82; p ¼ 0.056) in
fully-adjusted analysis. Associations with other ATD were as fol-
lows: SSRI: OR ¼ 1.20 (95% CI ¼ 0.89e1.62); TCA: OR ¼ 1.08 (95%
CI ¼ 0.61e1.94); other ATD: OR ¼ 0.80 (95% CI ¼ 0.37e1.70)
respectively. In neither of these analyses, depressive symptoms
demonstrated any signiﬁcant associations with nBRS (not
shown).
4. Discussion
In 9213men andwomen from the community aged 50e75 years
and who were offered a free extended clinical examination in a
large preventive health centre, antidepressant use was associated
with impaired (neural) baroreﬂex sensitivity as measured by ca-
rotid echotracking. These ﬁndings were independent of depressive
symptoms severity and several confounding factors and were
consistent after controlling for indication bias using propensity
score analyses. The effect size (OR¼ 1.34) was comparable to that of
hypertension, diabetes and was equivalent to the effect of 8 years of
ageing. Exploratory analysis further suggests a particularly strong
and signiﬁcant association with SNRI (OR ¼ 1.94). Instead, there
was no signiﬁcant association between high depressive symptoms
and lower (neural) baroreﬂex sensitivity.
4.1. Prior studies on depression and BRS
Only a few prior studies have investigated BRS in depressed
individuals and all were of very small sample size (n < 100). The
ﬁrst was performed in 30 stable CAD patients and reported
impaired BRS in those with depressive symptoms [12]. However,
Fig. 2. Odds ratios of low neural baroreﬂex sensitivity for antidepressant use: stratiﬁed analysis. Low nBRS: neural baroreﬂex sensitivity below the median value. The strata
for age and heart rate were deﬁned a priori according to the respective median value. Logistic regression analysis was adjusted for age (where appropriate), sex (where appropriate),
education, single status, smoking status, physical activity, body mass index, resting heart rate (where appropriate), past history of cardiovascular disease (where appropriate),
hypertension (where appropriate), diabetes, high depressive symptoms (where appropriate).
Fig. 3. Odds ratios of low neural baroreﬂex sensitivity for antidepressant use:
propensity score analysis. The propensity score of receiving ATD of any class was
estimated using logistic regression analysis and included age, sex, education, single
status, smoking status, physical activity, body mass index, resting heart rate, past
history of cardiovascular disease, hypertension, diabetes, high depressive symptoms as
predictors. For the propensity matching analysis, 1 subject under ATD was matched
with up to 4 controls using a difference in the probability of receiving ATD of less than
0.001, resulting in a study sample size of 2098 subjects. Low nBRS: neural baroreﬂex
sensitivity below the median value.
J.-P. Empana et al. / Atherosclerosis 251 (2016) 55e6260the impact of CAD per se on BRS impairment could not be
completely ruled out and, except age, other confounding factors
were not adjusted for. A second small study (n ¼ 62) reported
impaired BRS in patients with remitted depression as compared to
controls [13]. However this was a very selected population of
remitted depression patients with no risk factors. More recently, 2
population-based studies conducted in elderly subjects reported
impaired BRS in those with either major depression or high
depressive symptoms. In these 2 studies however, the contribution
of ATD use was not evaluated [14,15].4.2. BRS assessment
All these previous studies used non-invasive BRS assessmentmethods that relate spontaneous peripheral blood pressure change
with change in heart rate. Although widely used, this method is
highly inﬂuenced by the stiffness of the vascular wall: for the same
variation in blood pressure, the stiffer the artery, the smaller the
stretch, the smaller the signal applied on the baroreceptors and the
response in R-R interval, which will reduce the capacity to buffer
the pressure. This may have been a critical issue in the present
study that includes subjects aged 50e75 years, as the vascular wall
becomes stiffer with age [34]. This is the main reason why in the
present study, we preferred measuring BRS employing sponta-
neous carotid stretch change rather than peripheral blood pressure
change as the input signal using high precision carotid echotrack-
ing. With this technique, it is possible to study speciﬁcally the
neural component of the BRS, while controlling for the stiffness of
the carotid wall (i.e. the vascular or mechanical component of the
BRS) [33e36]. While the clinical relevance of a low BRS regarding
risk stratiﬁcation has been essentially shown with BRS measured
with invasive methods (infusion of vasoactive medications) [11,41],
recent preliminary results support that BRS as measured by carotid
echotracking might discriminate post MI patients at high risk for
arrhythmic events better than other noninvasive BRSmethods [42].
Still, we recognize that the data acquisition required particular skill,
and the analysis remained complex. Like other non-invasive BRS
methods, we assessed only one aspect of baroreﬂex regulation, the
baroreﬂex heart rate regulation, but not the baroreﬂex regulation of
vascular tone.4.3. Interpretation of the current ﬁndings
To the best of our knowledge, PPS3 is the ﬁrst large study con-
ducted in the community and addressing simultaneously the
relation between depressive symptomatology, ATD use and BRS.
We found that ATD use and not depressive symptoms, was asso-
ciated with impaired nBRS. The lack of association between
J.-P. Empana et al. / Atherosclerosis 251 (2016) 55e62 61depressive symptoms and impaired BRS does not preclude that an
association may exist with clinical depression, but the latter was
not measured in PPS3. There might be several explanations by
which ATD use is related to low nBRS in the current study. First, ATD
users may suffer from more severe depressive symptoms although
our study results were observed after adjustment for and stratiﬁ-
cation on depressive symptoms severity. Second, our ﬁndings may
reﬂect differences in the characteristics between ATD users and
non-users, and to underlying factors leading to the prescription of
ATD. However, we observed very consistent results after adjust-
ment for the baseline characteristics that differed between ATD
users and non-users, and after propensity score analyses that
control for indication bias of receiving ATD. Third and from a
pathophysiological view-point, association with BRS might reﬂect
an association with carotid stiffness, as CCA-IMT was signiﬁcantly
higher in ATD users compared to non-users in our study. As
mentioned previously, the method used to assess nBRS already
controls for the vascular component of the BRS (i.e. for arterial
stiffness) making this issue unlikely. Also, analysis stratiﬁed by
CCA-IMT level did not modify our study results (not shown). Still,
residual confounding cannot be excluded. For instance, anxiety
usually coexists with depressive symptoms and has been related to
impaired BRS in some studies, but anxiety was not collected at
baseline examination [43]. Also, depressed patients lack of adher-
ence to medications [44] so that our ﬁndings on ATD use might
reﬂect the lack of compliance to ATD rather than the effect of ATD
per se, but information on compliance to medication is hardly
available in such a large observational study conducted in the
community.
Our exploratory analysis suggests that the relationship between
ATD use and impaired BRS was essentially driven by SNRI use, and
venlafaxine in particular. This is consistent with the results of a
recent study showing that in patients with major depressive dis-
order randomly assigned to SSRI or SNRI, impaired BRS was noted
with SNRI only [45]. Elevated blood pressure, a frequent adverse
effect induced by SNRI drugs [46], and possibly reﬂecting an
alteration of the neural control of blood pressure, may contribute to
explain the lower nBRS in SNRI users as reported in the present
study. Coherently, Supplementary Table 2 points out higher systolic
blood pressure in SNRI (133 mmHg) than in SSRI (129 mmHg) and
TCA (129 mmHg) users; SNRI users were also taking more blood
pressure lowering drugs (26%) than SSRI (18%) or TCA (18%) users.
4.4. Implications and perspectives
In the current study, the effect size of the association between
ATD use and low nBRS was comparable to that with hypertension
or diabetes and was equivalent to the effect of 8 years of ageing,
making a chance ﬁnding unlikely, and suggesting the potential
clinical relevance of the study results. In particular, antidepressant
use should be considered carefully by physicians, particularly in
those patients with underlying cardiac disease. At present, our
ﬁndings may help clinicians to either adapt (for patients already
under a given ATD) or initiate the most appropriate ATD treatment
for their patients. Furthermore and from an intervention perspec-
tive, our study results reemphasized the role of physical activity as a
large body of evidence indicates its beneﬁcial effect on BRS and
possibly on depression [47,48]. However, as a ﬁrst study on nBRS,
depressive symptoms and ATD use in the community, the current
results need external validation. Prospective studies with repeated
evaluations of nBRS, depressive symptoms and ATD use will also
permit to test the temporality of these associations. In addition,
these prospective studies will allow testing our initial hypothesis,
i.e. that BRS alteration might mediate the association between
depression, ATD use and CVD onset. The PPS3 should be able toaddress some of these challenging issues in the coming years after
the completion of the follow-up and the validation of a sufﬁcient
numbers of CVD events including SCD.
4.5. Strengths and limitations
The large sample size, the use of very high precision echo-
trackingmeasure to assess BRS, the availability of several important
confounding factors, and the possibility to simultaneously investi-
gate depressive symptomatology and ATD use represent important
strengths. However, we acknowledge the following limitations. The
cross-sectional and observational nature of the analysis precludes
studying any temporal and causal relationship between high
depressive symptoms, ATD use and altered nBRS. Despite the high
concordance between high depressive symptoms as measured by
the 13-item questionnaire and clinical depression [27,32], clinical
diagnosed depression per se was not investigated here. We had no
information on the duration of depressive symptoms and on ATD
use precluding us to study dose-response relationships. We also
had no information on responsiveness to ATD.
To conclude, in a sample of 9213 men and women aged 50 to 75,
ATD use and SNRI use in particular but not high depressive symp-
toms was associated with low neural baroreﬂex sensitivity as
estimated by carotid echotracking. If conﬁrmed, these results may
bring novel insights in the putative mechanisms linking depressive
symptoms and/or ATD use with the onset of cardiovascular disease
and particularly SCD in the population.
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